Changes of natriuresis and prediction of cardiovascular events in patients with type 2 diabetes and decompensated heart failure over therapy with sodium-glucose cotransporter 2 inhibitors and standard diuretic therapy
Authors:
- O. A. AbdullaevOAO. A. Abdullaev
- A. G. ArutyunovAAA. G. Arutyunov
- D. P. VereshchakDVD. P. Vereshchak
- E. V. TavluevaETE. V. Tavlueva
- V. A. KonikVKV. A. Konik
- N. A. BylovaNBN. A. Bylova
- D. V. PuzenkoDPD. V. Puzenko
- N. P. KulaginaNKN. P. Kulagina
- I. R. NurievaINI. R. Nurieva
- T. V. ZaninaTZT. V. Zanina
- G. P. ArutyunovGAG. P. Arutyunov
Open Access
- 7 September 2023
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2) , 5602
Abstract
Aim. To evaluate the influence and changes of clinical and water-electrolyte parameters on the risk of cardiovascular events in the early period after decompensated heart failure (HF) in patients with type 2 diabetes (T2D), taking into account the influence of standard diuretic therapy and diuretic therapy in combination with sodium-glucose cotransporter 2 (SGLT-2) inhibitors.Material and methods. The study included 119 patients with type 2 diabetes and class III-IV HF. The duration of diagnosed HF at the time of enrollment was 6,9±1,1 years.Patients who met the inclusion criteria at the time of hospital admission were randomized into a group of standard therapy for decompensated HF (control group) and a group of combined diuretic therapy — loop diuretics + SGLT-2 inhibitors (main group).Results. Against the background of combined diuretic therapy with SGLT-2 inhibitors, a significant increase in diuresis was achieved, starting from the 2nd day: on day 2 — in the main group 1,342,83±159,74 ml/day and 1,250,17±134,53 ml/day in the control group (p=0,001, 95% confidence interval (CI)), on day 3, in the main — 1,895,17±249,95 ml/day, and in the control — 1,723,78±252,49 ml/day (p=0,004, 95% CI), on day 4, in the main — 2,382,50±246,29 ml/day and in the control — 2,124,83±2,86,44 ml/day (p=0,000002, 95% CI), on day 5, in the main — 2,785,50±282,38 ml/day and in the control group 2,458,39±273,36 ml/day (pConclusion. In patients with type 2 diabetes hospitalized for decompensated HF, therapy with SGLT-2 inhibitors + loop diuretics lead to a significantly greater diuresis, natriuresis and a greater decrease in extracellular fluid volume. A significant inverse relationship was found between the extracellular fluid volume and natriuresis level on day 5. Dapagliflozin effectiveness in edema, assessed by natriuresis level on day of treatment, is identical to the empagliflozin.Keywords
This publication has 19 references indexed in Scilit:
- Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysisEuropean Journal of Internal Medicine, 2022
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialNature Medicine, 2022
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureNew England Journal of Medicine, 2021
- Diuretic Strategies for Loop Diuretic Resistance in Acute Heart FailureJACC: Heart Failure, 2020
- Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)European Journal of Heart Failure, 2020
- Lung Ultrasound-Guided Treatment in Ambulatory Patients with Heart Failure: A Randomized Controlled Clinical Trial (LUS-HF Study)European Journal of Heart Failure, 2019
- Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart FailureJACC: Heart Failure, 2019
- Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failureInternational Journal of Cardiology, 2018
- Lung ultrasound and short-term prognosis in heart failure patientsInternational Journal of Cardiology, 2016
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011